• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于影像组学的机器学习模型预测P504s/P63免疫组化表达:一种前列腺癌的非侵入性诊断工具

Radiomics-Based Machine Learning Models for Predicting P504s/P63 Immunohistochemical Expression: A Noninvasive Diagnostic Tool for Prostate Cancer.

作者信息

Liu Yun-Fan, Shu Xin, Qiao Xiao-Feng, Ai Guang-Yong, Liu Li, Liao Jun, Qian Shuang, He Xiao-Jing

机构信息

Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Big Data and Software Engineering College, Chongqing University, Chongqing, China.

出版信息

Front Oncol. 2022 Jun 20;12:911426. doi: 10.3389/fonc.2022.911426. eCollection 2022.

DOI:10.3389/fonc.2022.911426
PMID:35795067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9252170/
Abstract

OBJECTIVE

To develop and validate a noninvasive radiomic-based machine learning (ML) model to identify P504s/P63 status and further achieve the diagnosis of prostate cancer (PCa).

METHODS

A retrospective dataset of patients with preoperative prostate MRI examination and P504s/P63 pathological immunohistochemical results between June 2016 and February 2021 was conducted. As indicated by P504s/P63 expression, the patients were divided into label 0 (atypical prostatic hyperplasia), label 1 (benign prostatic hyperplasia, BPH) and label 2 (PCa) groups. This study employed T2WI, DWI and ADC sequences to assess prostate diseases and manually segmented regions of interest (ROIs) with Artificial Intelligence Kit software for radiomics feature acquisition. Feature dimensionality reduction and selection were performed by using a mutual information algorithm. Based on screened features, P504s/P63 prediction models were established by random forest (RF), gradient boosting decision tree (GBDT), logistic regression (LR), adaptive boosting (AdaBoost) and k-nearest neighbor (KNN) algorithms. The performance was evaluated by the area under the ROC curve (AUC) and accuracy.

RESULTS

A total of 315 patients were enrolled. Among the 851 radiomic features, the 32 top features were derived from T2WI, in which the gray-level run length matrix (GLRLM) and gray-level cooccurrence matrix (GLCM) features accounted for the largest proportion. Among the five models, the RF algorithm performed best in general evaluations (microaverage AUC=0.920, macroaverage AUC=0.870) and provided the most accurate result in further sublabel prediction (the accuracies of label 0, 1, and 2 were 0.831, 0.831, and 0.932, respectively). In comparative sequence analyses, T2WI was the best single-sequence candidate (microaverage AUC=0.94 and macroaverage AUC=0.78). The merged datasets of T2WI, DWI, and ADC yielded optimal AUCs (microaverage AUC=0.930 and macroaverage AUC=0.900).

CONCLUSIONS

The radiomic-based RF classifier has the potential to be used to evaluate the presurgical P504s/P63 status and further diagnose PCa noninvasively and accurately.

摘要

目的

开发并验证一种基于放射组学的非侵入性机器学习(ML)模型,以识别P504s/P63状态,进而实现前列腺癌(PCa)的诊断。

方法

对2016年6月至2021年2月期间进行术前前列腺MRI检查及P504s/P63病理免疫组化结果的患者进行回顾性数据集研究。根据P504s/P63表达情况,将患者分为标签0(非典型前列腺增生)、标签1(良性前列腺增生,BPH)和标签2(PCa)组。本研究采用T2WI、DWI和ADC序列评估前列腺疾病,并使用人工智能套件软件手动分割感兴趣区域(ROIs)以获取放射组学特征。通过互信息算法进行特征降维和选择。基于筛选出的特征,采用随机森林(RF)、梯度提升决策树(GBDT)、逻辑回归(LR)、自适应提升(AdaBoost)和k近邻(KNN)算法建立P504s/P63预测模型。通过ROC曲线下面积(AUC)和准确率评估模型性能。

结果

共纳入315例患者。在851个放射组学特征中,32个顶级特征来自T2WI,其中灰度游程长度矩阵(GLRLM)和灰度共生矩阵(GLCM)特征占比最大。在五个模型中,RF算法在总体评估中表现最佳(微平均AUC = 0.920,宏平均AUC = 0.870),并在进一步的子标签预测中提供了最准确的结果(标签0、1和2的准确率分别为0.831、0.831和0.932)。在比较序列分析中,T2WI是最佳的单序列候选者(微平均AUC = 0.94,宏平均AUC = 0.78)。T2WI、DWI和ADC的合并数据集产生了最佳的AUC(微平均AUC = 0.930,宏平均AUC = 0.900)。

结论

基于放射组学的RF分类器有潜力用于术前评估P504s/P63状态,并进一步无创、准确地诊断PCa。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/ad0053491e72/fonc-12-911426-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/73cbae4f2170/fonc-12-911426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/72e266a5f930/fonc-12-911426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/e686854b108d/fonc-12-911426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/8b0f5b300907/fonc-12-911426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/53d6e7d1d0f5/fonc-12-911426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/ad0053491e72/fonc-12-911426-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/73cbae4f2170/fonc-12-911426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/72e266a5f930/fonc-12-911426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/e686854b108d/fonc-12-911426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/8b0f5b300907/fonc-12-911426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/53d6e7d1d0f5/fonc-12-911426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43b1/9252170/ad0053491e72/fonc-12-911426-g006.jpg

相似文献

1
Radiomics-Based Machine Learning Models for Predicting P504s/P63 Immunohistochemical Expression: A Noninvasive Diagnostic Tool for Prostate Cancer.基于影像组学的机器学习模型预测P504s/P63免疫组化表达:一种前列腺癌的非侵入性诊断工具
Front Oncol. 2022 Jun 20;12:911426. doi: 10.3389/fonc.2022.911426. eCollection 2022.
2
MRI Radiomics-Based Machine Learning Models for Ki67 Expression and Gleason Grade Group Prediction in Prostate Cancer.基于MRI影像组学的机器学习模型用于预测前列腺癌中的Ki67表达和Gleason分级组
Cancers (Basel). 2023 Sep 13;15(18):4536. doi: 10.3390/cancers15184536.
3
A machine learning radiomics model based on bpMRI to predict bone metastasis in newly diagnosed prostate cancer patients.一种基于bpMRI的机器学习放射组学模型,用于预测新诊断前列腺癌患者的骨转移。
Magn Reson Imaging. 2024 Apr;107:15-23. doi: 10.1016/j.mri.2023.12.009. Epub 2024 Jan 3.
4
Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.基于双参数 MRI 放射组学特征预测前列腺癌分级。
Contrast Media Mol Imaging. 2021 Dec 23;2021:7830909. doi: 10.1155/2021/7830909. eCollection 2021.
5
Radiomic-based machine learning model for the accurate prediction of prostate cancer risk stratification.基于放射组学的机器学习模型用于准确预测前列腺癌风险分层。
Br J Radiol. 2023 Mar;96(1143):20220238. doi: 10.1259/bjr.20220238. Epub 2023 Jan 4.
6
Comparison of Machine Learning Models Using Diffusion-Weighted Images for Pathological Grade of Intrahepatic Mass-Forming Cholangiocarcinoma.基于扩散加权成像的机器学习模型对肝内肿块型胆管细胞癌病理分级的比较。
J Imaging Inform Med. 2024 Oct;37(5):2252-2263. doi: 10.1007/s10278-024-01103-z. Epub 2024 Apr 16.
7
Predicting Histopathological Grading of Adult Gliomas Based On Preoperative Conventional Multimodal MRI Radiomics: A Machine Learning Model.基于术前常规多模态MRI影像组学预测成人胶质瘤的组织病理学分级:一种机器学习模型
Brain Sci. 2023 Jun 5;13(6):912. doi: 10.3390/brainsci13060912.
8
Differential Diagnosis of Prostate Cancer Grade to Augment Clinical Diagnosis Based on Classifier Models with Tuned Hyperparameters.基于具有调优超参数的分类器模型对前列腺癌分级进行鉴别诊断以加强临床诊断
Cancers (Basel). 2024 Jun 6;16(11):2163. doi: 10.3390/cancers16112163.
9
Leveraging multimodal MRI-based radiomics analysis with diverse machine learning models to evaluate lymphovascular invasion in clinically node-negative breast cancer.利用基于多模态磁共振成像的影像组学分析和多种机器学习模型评估临床腋窝淋巴结阴性乳腺癌中的淋巴管侵犯情况。
Heliyon. 2023 Dec 18;10(1):e23916. doi: 10.1016/j.heliyon.2023.e23916. eCollection 2024 Jan 15.
10
Comparison between Three Radiomics Models and Clinical Nomograms for Prediction of Lymph Node Involvement in PCa Patients Combining Clinical and Radiomic Features.结合临床和影像组学特征的三种影像组学模型与临床列线图在预测前列腺癌患者淋巴结受累情况中的比较
Cancers (Basel). 2024 Jul 31;16(15):2731. doi: 10.3390/cancers16152731.

引用本文的文献

1
Intralesional and perilesional radiomics strategy based on different machine learning for the prediction of international society of urological pathology grade group in prostate cancer.基于不同机器学习方法的瘤内及瘤周影像组学策略用于预测前列腺癌国际泌尿病理学会分级组
BMC Med Imaging. 2025 Jul 4;25(1):266. doi: 10.1186/s12880-025-01812-z.
2
Clinical-radiomics combination model for predicting the short-term efficacy of bipolar transurethral enucleation of the prostate in patients with benign prostatic hyperplasia.预测良性前列腺增生患者双极经尿道前列腺剜除术短期疗效的临床-放射组学联合模型
Curr Urol. 2025 Jan;19(1):30-38. doi: 10.1097/CU9.0000000000000256. Epub 2024 Sep 3.
3

本文引用的文献

1
Differentiating prostate cancer from benign prostatic hyperplasia using whole-lesion histogram and texture analysis of diffusion- and T2-weighted imaging.利用弥散加权和 T2 加权成像的全病变直方图和纹理分析鉴别前列腺癌与良性前列腺增生。
Cancer Imaging. 2021 Sep 27;21(1):54. doi: 10.1186/s40644-021-00423-5.
2
Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.基于机器学习技术的前列腺癌诊断增强:一项算法研发与验证研究。
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):672-676. doi: 10.1038/s41391-021-00429-x. Epub 2021 Jul 15.
3
A novel computer-aided diagnostic system for accurate detection and grading of liver tumors.
AI for BPH Surgical Decision-Making: Cost Effectiveness and Outcomes.
AI 在 BPH 手术决策中的应用:成本效益与结果。
Curr Urol Rep. 2024 Sep 23;26(1):4. doi: 10.1007/s11934-024-01240-6.
4
Radiomic Pipelines for Prostate Cancer in External Beam Radiation Therapy: A Review of Methods and Future Directions.适形调强放疗中前列腺癌的影像组学流程:方法与未来方向综述
J Clin Med. 2024 Jul 3;13(13):3907. doi: 10.3390/jcm13133907.
5
Comparison of MRI Sequences to Predict Mutation Status in Gliomas Using Radiomics-Based Machine Learning.使用基于影像组学的机器学习比较MRI序列以预测胶质瘤的突变状态
Biomedicines. 2024 Mar 25;12(4):725. doi: 10.3390/biomedicines12040725.
6
A noninvasive method for predicting clinically significant prostate cancer using magnetic resonance imaging combined with PRKY promoter methylation level: a machine learning study.一种使用磁共振成像结合PRKY启动子甲基化水平预测临床显著前列腺癌的非侵入性方法:一项机器学习研究。
BMC Med Imaging. 2024 Mar 11;24(1):60. doi: 10.1186/s12880-024-01236-1.
7
Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects.基于磁共振成像的放射组学和人工智能在前列腺癌中的进展:全面综述与未来展望
Cancers (Basel). 2023 Jul 28;15(15):3839. doi: 10.3390/cancers15153839.
8
Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer.用于前列腺癌临床诊断与治疗的人工智能
Cancers (Basel). 2022 Nov 14;14(22):5595. doi: 10.3390/cancers14225595.
9
Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach.地诺单抗时代脊柱骨巨细胞瘤RANKL表达的预后价值及定量CT分析:一种机器学习方法
Cancers (Basel). 2022 Oct 23;14(21):5201. doi: 10.3390/cancers14215201.
一种用于准确检测和分级肝肿瘤的新型计算机辅助诊断系统。
Sci Rep. 2021 Jun 23;11(1):13148. doi: 10.1038/s41598-021-91634-0.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
6
Value of MRI texture analysis for predicting high-grade prostate cancer.MRI 纹理分析在预测高级别前列腺癌中的价值。
Clin Imaging. 2021 Apr;72:168-174. doi: 10.1016/j.clinimag.2020.10.028. Epub 2020 Oct 24.
7
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南-2020 版更新。第 1 部分:筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
8
Ada-WHIPS: explaining AdaBoost classification with applications in the health sciences.Ada-WHIPS:解释 AdaBoost 分类及其在健康科学中的应用。
BMC Med Inform Decis Mak. 2020 Oct 2;20(1):250. doi: 10.1186/s12911-020-01201-2.
9
Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.前瞻性 PI-RADS v2.1 伴显著弥散受限的不典型前列腺增生结节:多参数 MRI 检测临床显著前列腺癌。
AJR Am J Roentgenol. 2021 Aug;217(2):395-403. doi: 10.2214/AJR.20.24370. Epub 2020 Sep 2.
10
Automated Classification of Significant Prostate Cancer on MRI: A Systematic Review on the Performance of Machine Learning Applications.MRI 上显著前列腺癌的自动分类:机器学习应用性能的系统评价
Cancers (Basel). 2020 Jun 17;12(6):1606. doi: 10.3390/cancers12061606.